What AbCellera Biologics (ABCL) said on its Q3 earnings call. AbCellera Biologics (NASDAQ:ABCL) plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further development of a separate antibody candidate for now. On its third-quarter earnings call, the company also reported a narrower net loss and said it had more than $890 million in available liquidity, including committed government funding. Hot flash treatment moves toward late-stage studies. ABCL635 is an investigational non-hormonal antibody for moderate to severe vasomotor symptoms, or hot flashes. The Phase II trial evaluated efficacy and safety four weeks after a single 600-milligram injection. At four weeks, patients receiving ABCL635 had an average reduction of 8.8 moderate or severe hot flashes per day, compared with a reduction of 3.5 per day in the placebo group, President and CEO Carl Hansen said. That represented an 83% reduction from baseline for the treatment group, compared with 33% for placebo. Mean severity scores fell 1.4 points in the treatment group and 0.3 points in the placebo group. Hansen said 37% of treated participants reported complete resolution of moderate or severe events at four weeks, compared with 2.2% of those receiving placebo. Hansen said the observed treatment effect compared favorably with results from separate studies of approved non-hormonal therapies fezolinetant and elinzanetant, while acknowledging the limitations of cross-trial comparisons. More patients receiving ABCL635 reported at least one adverse event than those on placebo, but there were no serious or severe adverse events in the treatment group during the first four weeks, Hansen said. Headache and fatigue were reported more frequently among treated patients. He said the study showed no evidence of gastrointestinal toxicity or a clear signal of liver toxicity. AbCellera expects to release additional 12-week and open-label extension data in early 2027. Chief Medical Officer Sarah Noonberg said the company does not expect efficacy from the single dose to be maintained throughout the full 12 weeks; the later observations are intended to help model the relationship between drug exposure and response for dose selection. The company is working with the Food and Drug Administration through its Model-Informed Drug Development program and expects to begin late-stage studies in 2027. It also plans trials next year in patients experiencing hot flashes associated with breast and prostate cancer treatments. New pipeline programs and ABCL575 decision. AbCellera introduced ABCL992, a longer-acting version of ABCL635 that entered activities required to support an investigational new drug application in the third quarter. Hansen said the company is not yet ready to disclose how it will position the two products, but emphasized that it remains committed to ABCL635. Hansen said ABCL992 is not expected to enter clinical trials in 2027 and could do so in 2028. Two other candidates, ABCL688 and ABCL386, are on timelines that would bring them into the clinic in 2027, he said. The company also announced ABCL385, an oncology program for an undisclosed indication, and ABCL646, an antibody antagonist against an undisclosed ion channel target. AbCellera does not expect to provide further details on those programs until they enter clinical development. Separately, AbCellera said it does not currently plan to develop ABCL575 beyond Phase I. Hansen attributed the decision to disappointing results for other therapies targeting the OX40 pathway in atopic dermatitis. Noonberg said ABCL575 showed favorable tolerability and pharmacokinetics in a study of 40 healthy volunteers. About 57% of participants receiving the antibody reported at least one adverse event, compared with 60% on placebo. The observed mean half-life was approximately 55 days, supporting potential dosing once a quarter or less frequently, she said. Loss narrows as liquidity tops $890 million. Third-quarter revenue was more than $10 million, compared with approximately $9 million a year earlier, and consisted mostly of research fees, Chief Financial Officer Andrew Booth said. Research and development expenses were approximately $44 million, while sales, general and administrative expenses were approximately $14 million. AbCellera reported a net loss of roughly $41 million, or $0.13 per share, compared with a loss of about $57 million in the prior-year quarter. Booth attributed the decline in administrative expenses in part to the conclusion of intellectual property litigation and team changes associated with the company's focus on its internal pipeline. The company ended the quarter with more than $790 million in cash and marketable securities after completing a $200 million equity raise. Including more than $100 million in available committed government funding, AbCellera had over $890 million in available liquidity, Booth said. He said the company believes it has sufficient liquidity to fund at least the next three years of pipeline investments. About AbCellera Biologics (NASDAQ:ABCL). AbCellera Biologics Inc is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases. Founded in 2012, AbCellera has collaborated with global partners, including Eli Lilly, on antibody treatments for COVID-19.

AbCellera Biologics (NASDAQ:ABCL) releases earnings results, beats estimates by $0.04 EPS. November 9, 2026 Key points. * AbCellera reported quarterly EPS of -$0.13, beating analyst expectations of -$0.17, while revenue of $10.64 million topped estimates of $8.41 million. * Its ABCL635 Phase II study showed an 83% reduction in daily moderate-to-severe hot flashes after four weeks, compared with 33% for placebo; the company expects to advance the drug into late-stage development in 2027. * Following a $200 million equity raise, AbCellera reported more than $790 million in cash and marketable securities and said it has funding for at least three years of pipeline investment. * Five stocks to consider instead of AbCellera Biologics. AbCellera Biologics (NASDAQ:ABCL - Get Free Report) posted its quarterly earnings data on Monday. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.04, FiscalAI reports. AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. The company had revenue of $10.64 million for the quarter, compared to analyst estimates of $8.41 million. Here are the key takeaways from AbCellera Biologics' conference call: * AbCellera reported strong four-week Phase II results for ABCL635, with an 83% reduction in daily moderate-to-severe hot flashes versus 33% on placebo, and no clear gastrointestinal or liver-toxicity signal. The company cautioned that the study assessed a single dose and that comparisons with other treatments are cross-trial. * The company plans to advance ABCL635 into late-stage development in 2027 and expects to release 12-week and open-label extension data in early 2027. It also plans to study the drug for treatment-related hot flashes in breast and prostate cancer patients, while a longer-acting follow-on, ABCL992, entered IND-enabling work. * After completing an oversubscribed $200 million equity raise, AbCellera reported more than $790 million in cash and marketable securities and over $890 million in available liquidity including committed government funding. Management said it has funding for at least three years of pipeline investment. * AbCellera added three programs - ABCL992, an oncology program, and an ion-channel-targeting antibody - and said ABCL688 and ABCL386 remain in IND-enabling work, with both potentially entering clinical trials in 2027. * Despite favorable Phase I tolerability and pharmacokinetic results for ABCL575, AbCellera does not plan to advance it beyond Phase I, citing setbacks for other drugs targeting the OX40/OX40L pathway. AbCellera Biologics price performance. Shares of NASDAQ:ABCL traded up $0.62 during mid-day trading on Monday, hitting $12.50. The company had a trading volume of 2,945,557 shares, compared to its average volume of 5,858,420. The firm has a fifty day moving average price of $12.28 and a 200 day moving average price of $7.04. The company has a market capitalization of $3.83 billion, a PE ratio of -23.15 and a beta of 1.59. AbCellera Biologics has a one year low of $2.74 and a one year high of $15.02. Analyst upgrades and downgrades. ABCL has been the topic of several recent analyst reports. The Goldman Sachs Group began coverage on shares of AbCellera Biologics in a report on Thursday, September 24th. They issued a "neutral" rating and a $13.00 target price on the stock. JPMorgan Chase & Co. began coverage on AbCellera Biologics in a report on Tuesday, September 29th. They set an "overweight" rating and a $17.00 price target for the company. Jefferies Financial Group assumed coverage on AbCellera Biologics in a research report on Friday, October 30th. They issued a "buy" rating and a $21.00 price objective for the company. UBS Group assumed coverage on AbCellera Biologics in a research note on Monday, October 12th. They issued a "buy" rating and a $18.00 price objective on the stock. Finally, Stifel Nicolaus upped their target price on AbCellera Biologics from $8.00 to $9.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $15.78. About AbCellera Biologics. AbCellera Biologics Inc is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases. Founded in 2012, AbCellera has collaborated with global partners, including Eli Lilly, on antibody treatments for COVID-19. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider AbCellera Biologics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list. While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential. Continue following MarketBeat